Mirzaie Vida, Eslaminejad Touba, Sheikhbahaei Fatemeh, Vafaei Shayan, Nabipour Fatemeh, Behzadi Mina, Nematollahi-Mahani Seyed Noureddin
Department of Anatomical Science, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Basic Med Sci. 2025;28(9):1171-1179. doi: 10.22038/ijbms.2025.85417.18468.
Cannabinoids, derivatives of L., can activate the endocannabinoid system via two endogenous receptors, CB1 and CB2. This system is crucial in regulating folliculogenesis, fertility, and reproductive function. This study investigated the potential effects of cannabinoid agonists and antagonists on ovarian health and function in female mice.
80 NMRI mice were divided into 10 groups. Treatment groups received CB1 or CB2 agonists, antagonists, or their combinations for five days. The animals were then sacrificed, the ovaries were excised and weighed, and their volume was measured. Total RNA was extracted from the left ovary for qPCR analysis, while the right ovary was fixed in Bouin's solution for histological evaluation following H&E staining.
Treatment with CB1/CB2 agonist+CB1 antagonist (W102+AM251) decreased the level of NAPE-PLD (a key factor in the production of endocannabinoids in cells) and increased the level of FAAH (responsible for cannabinoid degradation) genes compared to all groups. CB2 antagonist (AM630) increased the number of primary, preantral, and antral follicles, the volume and weight of ovaries, and estrogen levels. Meanwhile, the CB1 antagonist (AM251) significantly increased microvascular density in the ovaries.
Cannabinoids modulate ovarian physiology and folliculogenesis, with CB2 receptors playing a particularly significant role. Antagonism at CB2 appeared to differentially affect cannabinoid-metabolizing enzymes in ovarian follicles and differentially affect their maturation. However, our preliminary novel findings in mice require human studies before clinical application.
大麻素是大麻的衍生物,可通过两种内源性受体CB1和CB2激活内源性大麻素系统。该系统在调节卵泡发生、生育能力和生殖功能方面至关重要。本研究调查了大麻素激动剂和拮抗剂对雌性小鼠卵巢健康和功能的潜在影响。
将80只NMRI小鼠分为10组。治疗组接受CB1或CB2激动剂、拮抗剂或其组合治疗5天。然后处死动物,切除卵巢并称重,测量其体积。从左侧卵巢提取总RNA用于qPCR分析,而右侧卵巢固定在Bouin氏液中,经苏木精-伊红染色后进行组织学评估。
与所有组相比,用CB1/CB2激动剂+CB1拮抗剂(W102+AM251)治疗可降低NAPE-PLD(细胞内源性大麻素产生的关键因子)水平,并增加FAAH(负责大麻素降解)基因水平。CB2拮抗剂(AM630)增加了初级卵泡、窦前卵泡和窦卵泡的数量、卵巢体积和重量以及雌激素水平。同时,CB1拮抗剂(AM251)显著增加了卵巢中的微血管密度。
大麻素调节卵巢生理和卵泡发生,其中CB2受体发挥着特别重要的作用。对CB2的拮抗作用似乎对卵巢卵泡中大麻素代谢酶有不同影响,并对其成熟有不同影响。然而,我们在小鼠中的初步新发现需要在临床应用前进行人体研究。